Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease.
The cerebrospinal fluid is a valuable diagnostic fluid that is underutilized. A number of classical neurochemical tests and newer biomarkers of neuropathology may be performed on the cerebrospinal fluid from patients with clinical signs of progressive neurological disease to assist and complement diagnosis. Here, we discuss how they may be employed in the clinical evaluation of patients with memory problems. We argue for their proper application and use, and caution against common misinterpretations.
Institute of Neuroscience & Physiology, Department of Psychiatry & Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. henrik.zetterberg@gu.se
Henrik
H
Zetterberg
Michael P
MP
Lunn
Sanna-Kaisa
SK
Herukka
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000473:pathology; D006801:Humans; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D016875:tau Proteins / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins